Related Experiment Video
Updated: Jun 4, 2026
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
GPR54 is a target for suppression of metastasis in endometrial cancer
Hyun Sook Kang1, Tsukasa Baba, Masaki Mandai
1Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, Kyoto 606-8507, Japan.
Abstract:
Invasion into deep myometrium and/or lymphovascular space is a well-known risk factor for endometrial cancer metastasis, resulting in poor prognosis. It is therefore clinically important to identify novel molecules that suppress tumor invasion. Reduced expression of the metastasis suppressor, kisspeptin (KISS1), and its endogenous receptor, GPR54, has been reported in several cancers, but the significance of the KISS1/GPR54 axis in endometrial cancer metastasis has not been clarified. Metastin-10 is the minimal bioactive sequence of genetic products of KISS1. Clinicopathological analysis of 92 endometrial cancers revealed overall survival is improved in cancers with high expression of GPR54 (P < 0.05) and that GPR54 expression is associated with known prognostic factors including FIGO stage, grade, and deep myometrial invasion. Through RNAi and microarray analyses, metastin-10 was predicted to suppress metastasis of GPR54-expressing endometrial cancers in vivo. Methylation analysis revealed GPR54 is epigenetically regulated. Metastin-GPR54 axis function was restored following treatment with the DNA hypomethylating agent 5-aza-DC. These data suggest that metastin-10 may be effective at inhibiting the metastatic spread of endometrial cancers in combination with demethylating agents to induce GPR54 expression.
Insights
High GPR54 expression improves survival in endometrial cancer. Metastin-10 may suppress metastasis, especially when combined with demethylating agents to restore GPR54 expression.
Area of Science:
- Oncology
- Molecular Biology
Background:
- Deep myometrial invasion and lymphovascular space invasion are key risk factors for endometrial cancer metastasis and poor prognosis.
- The KISS1/GPR54 axis, a known metastasis suppressor, has an unclear role in endometrial cancer.
- Identifying novel metastasis suppressors is crucial for improving patient outcomes.
Purpose of the Study:
- To investigate the role of the KISS1/GPR54 axis in endometrial cancer metastasis.
- To evaluate the potential of metastin-10 as a therapeutic agent against endometrial cancer spread.
- To explore the epigenetic regulation of GPR54 in endometrial cancer.
Main Methods:
- Clinicopathological analysis of 92 endometrial cancer cases.
- RNA interference (RNAi) and microarray analyses to assess metastin-10's effect.
- Methylation analysis and treatment with 5-aza-DC (a DNA hypomethylating agent).
Main Results:
- High GPR54 expression correlated with improved overall survival in endometrial cancer patients (P < 0.05).
- GPR54 expression was significantly associated with established prognostic factors like FIGO stage, grade, and myometrial invasion depth.
- Metastin-10 showed potential to suppress metastasis in GPR54-expressing endometrial cancers in vivo.
- GPR54 expression is epigenetically regulated and its function can be restored by 5-aza-DC.
Conclusions:
- The KISS1/GPR54 axis is a significant factor in endometrial cancer progression and prognosis.
- Metastin-10 holds promise for inhibiting endometrial cancer metastasis.
- Combining metastin-10 with demethylating agents could be a viable therapeutic strategy by restoring GPR54 expression.
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:15G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...